Larazotide vs BPC-157.

Larazotide (larazotide acetate, research code AT-1001) is a synthetic eight-amino-acid peptide investigated as an oral, gut-restricted therapy for celiac disease. It was designed to act locally in the small intestine rather than being absorbed systemically. The concept was to add a first non-dietary treatment for patients who still have symptoms despite a gluten-free diet. It advanced through Phase 2 and into Phase 3 development but is not approved by the FDA or any major regulator. It is categorized under healing because its target is intestinal barrier repair and integrity.

BPC-157 (sometimes written PL 14736 or "Body Protection Compound 157") is a synthetic pentadecapeptide, a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419 Da). It was designed as a stable partial sequence derived from a larger protein reported in human gastric juice, and is studied chiefly as a cytoprotective and tissue-healing agent. It is not a naturally occurring hormone or an approved drug; nearly all of its reputation rests on animal experiments.

Larazotide is a tight-junction regulator, often described as a zonulin antagonist. In celiac disease, gluten exposure is associated with increased release of zonulin and loosening of the tight junctions between intestinal epithelial cells, allowing gluten peptides to cross the barrier and drive immune activation. Larazotide is proposed to promote tight-junction assembly and reduce paracellular permeability (leaky gut), thereby limiting gluten peptide entry and downstream inflammation. It is intended to work in the gut lumen, which fits its minimal systemic absorption. The precise molecular target and the physiological role of zonulin itself remain areas of scientific debate.

BPC-157's most consistently reported mechanism is modulation of the nitric oxide (NO) system: it promotes endothelial NO production and its protective and vasoactive effects are blunted by NO-synthase blockade (e.g., L-NAME) in animal and tissue models. In endothelial cells it has been reported to activate a Src–caveolin-1–eNOS pathway and to enhance VEGFR2-driven signaling, which is the proposed basis for its pro-angiogenic ("new blood vessel") effects on healing tissue. In cultured tendon fibroblasts it upregulates the growth hormone receptor and supports cell survival and migration. It is also described as interacting with multiple cytoprotective and neurotransmitter (e.g., dopaminergic, serotonergic) systems, though these are largely inferred from preclinical pharmacology rather than direct human data.

Mid-stage data were encouraging but the definitive trial did not succeed. In a Phase 2b randomized, double-blind, placebo-controlled trial (Leffler et al., Gastroenterology, 2015; 342 patients with persistent symptoms despite a gluten-free diet), low-dose larazotide reduced patient-reported symptoms versus placebo, with the lowest dose showing the clearest signal. On the strength of such results the program advanced to a large Phase 3 trial (CeD-2001) run by 9 Meters Biopharma. That Phase 3 study was halted after an interim analysis indicated it was unlikely to meet its primary endpoint, the change from baseline in celiac symptom severity, effectively ending the program. In short: positive Phase 2b data did not translate into a successful Phase 3 result, and larazotide is not an approved therapy. Several features of the earlier evidence look different in hindsight. The Phase 2b result was strongest at the lowest dose tested, without a conventional dose-response relationship, a pattern that is difficult to interpret mechanistically and that often does not reproduce. Primary endpoints across the program were patient-reported symptom scores rather than histology or objective mucosal healing, and symptom scores in celiac disease are noisy and prone to large placebo responses. Supporting biology exists outside these trials: larazotide acetate promoted recovery of ischemia-injured porcine jejunum through repair of tight junctions (PLoS One, 2021), and reviews of celiac pharmacotherapy place tight-junction regulation among several strategies that have been tried without yet producing an approved drug (European Journal of Pharmacology, 2021). The comparison that matters is with existing management. A strict lifelong gluten-free diet remains the only established treatment for celiac disease, supported by decades of clinical experience and by histologic and serologic recovery in patients who adhere to it. No drug has been approved as an adjunct or replacement. Larazotide reached the last stage of testing and failed there, so the honest summary is that the leading non-dietary candidate did not demonstrate benefit when tested at confirmatory scale.

The evidence base is overwhelmingly preclinical: hundreds of rodent and in vitro studies (a large fraction from a single Croatian research group led by Predrag Sikiric) report accelerated healing of tendon, muscle, ligament, bone, gut, and nervous tissue, plus gastrointestinal cytoprotection. Human evidence is extremely thin: there is no completed, published, adequately powered randomized controlled trial demonstrating a clinical benefit, and reports of human use (e.g., small uncontrolled case series for joint pain, and an early-phase inflammatory bowel disease program under the code PL 14736) are limited, often unpublished, lack placebo controls, and represent the lowest tiers of clinical evidence. Mechanistic and animal plausibility for tissue repair is genuinely interesting, but it has NOT been confirmed to translate into proven efficacy or safety in people. Any claim that BPC-157 reliably heals injuries in humans goes beyond what the published data support.

Across trials larazotide was generally well tolerated, consistent with a peptide that acts locally in the gut and is minimally absorbed. Reported adverse events were typically mild and gastrointestinal, such as abdominal discomfort, nausea, or headache, and were often similar between drug and placebo groups. Minimal systemic absorption limits the plausibility of effects outside the intestinal lumen, and no distinctive organ toxicity emerged as a program-stopping signal; the Phase 3 trial was discontinued for likely futility on efficacy, not for safety. Because development stopped before approval, there is no long-term real-world safety dataset in a broad treated population. Clinical trial exposure was limited in duration and confined to selected participants who met entry criteria, so effects of use over years, in children, in pregnancy, in older patients with comorbidities, or alongside common medications were never characterized. There is no post-marketing pharmacovigilance stream because there is no marketed product, and no regulator has reviewed a complete safety dossier. Anything sold as larazotide outside a clinical trial carries the separate risks of unapproved supply: no verified identity or purity, no batch testing, no good manufacturing practice oversight, and no adverse-event reporting. There is also an indirect risk specific to celiac disease, since any product presented as protection against gluten exposure could encourage relaxation of the gluten-free diet, which remains the only established management and the only intervention shown to allow mucosal recovery. This entry is educational only and is not a recommendation to obtain or use the compound, which is not an approved medicine.

There is no robust human safety dataset: long-term controlled toxicology and pharmacokinetic data in people are essentially absent, so its safety profile in humans is genuinely unknown. Animal studies have generally reported low acute toxicity, but rodent safety does not establish human safety, and theoretical concerns exist given its angiogenic (blood-vessel-promoting) activity, including unstudied implications for tumor biology. Most material sold online is research-use-only product of unverified identity, purity, and sterility, which adds contamination and mislabeling risks independent of the peptide itself. This entry intentionally gives no dosing, route, or protocol information.

Larazotide is investigational and is not approved by the FDA or EMA for celiac disease or any other indication. It reached Phase 3, but the pivotal CeD-2001 trial was discontinued for likely futility on its primary endpoint. Any product sold as larazotide outside of a clinical trial is not an approved drug.

BPC-157 is not approved by the FDA (or other major regulators) for any indication and remains an investigational/research-use-only compound. The FDA placed it in Category 2 of the 503A bulk-substances review in 2023 (citing significant safety questions and restricting compounding); reporting in 2026 indicates it was later removed from that Category 2 list amid a renewed review; removal is not approval and does not establish safety or efficacy.